Can-Fite BioPharma (CANF) files proxy materials for Special Meeting

Can-Fite BioPharma Ltd. furnished a Notice and Proxy Statement, a Proxy Card for ordinary shareholders, and a Voting Instruction Card for American Depositary Shareholders in connection with a Special General Meeting of Shareholders.

Rhea-AI Filing Summary

Can-Fite BioPharma Ltd. furnished a Notice and Proxy Statement, a Proxy Card for ordinary shareholders, and a Voting Instruction Card for American Depositary Shareholders in connection with a Special General Meeting of Shareholders. The report is dated October 3, 2025 and is signed by Motti Farbstein, who is listed as Chief Executive Officer and Chief Financial Officer. The filing incorporates prior registration statements by reference to the extent not superseded.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Can-Fite BioPharma (CANF) file in this 6-K?

The company furnished a Notice and Proxy Statement, a Proxy Card for ordinary shareholders, and a Voting Instruction Card for American Depositary Shareholders.

What is the date on the Can-Fite BioPharma (CANF) current report?

The report is dated October 3, 2025.

Who signed the Can-Fite BioPharma (CANF) 6-K?

The filing is signed by Motti Farbstein, identified as Chief Executive Officer and Chief Financial Officer.

Is the 6-K disclosing any transactions or financial data?

No. The filing furnishes meeting materials and incorporates prior registration statements by reference; it does not include financial tables or transaction details.

Who should use the Proxy Card and Voting Instruction Card in this filing?

Ordinary shareholders should use the Proxy Card, while holders of American Depositary Shares should use the Voting Instruction Card.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/03/2025 - 04:15 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of October 2025

001-36203

(Commission File Number)

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

26 Ben Gurion Street

Ramat Gan 5257346, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F þ Form 40-F ☐

This Report on Form 6-K (including exhibits thereto) is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File Nos. 333-227753, 333-271384 and 333-278525) and Form F-3 (File Nos. 333-236064, 333-274316, 333-262055, 333-276000 and 333-281872), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

On October 3, 2025, Can-Fite BioPharma Ltd. (the “Company”) announced that it will hold a Special General Meeting of Shareholders on November 3, 2025, at 3.00 p.m. (Israel time) at the Company’s offices at 26 Ben Gurion Street, Ramat Gan, Israel. In connection with the meeting, the Company furnishes the following documents:

1. A copy of the Notice and Proxy Statement with respect to the Company’s Special General Meeting of Shareholders describing the proposal to be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other details related to the meeting, attached hereto as Exhibit 99.1;

2. A form of Proxy Card whereby holders of ordinary shares of the Company may vote at the meeting without attending in person, attached hereto as Exhibit 99.2; and

3. A form of Voting Instruction Card whereby holders of American Depositary Shares of the Company may vote at the meeting without attending in person, attached hereto as Exhibit 99.3.

1

Exhibit Index

Exhibit No.		Description
99.1		Notice and Proxy Statement with respect to the Company’s Special General Meeting of Shareholders
99.2		Proxy Card for holders of ordinary shares with respect to the Company’s Special General Meeting of Shareholders
99.3		Voting Instruction Card for American Depositary Shareholders with respect to the Company’s Special General Meeting of Shareholders

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: October 3, 2025	By:	/s/ Motti Farbstein
		Motti Farbstein
		Chief Executive Officer and Chief Financial Officer

3